Investors

Investors

Company Information

 

Agenus is an immuno-oncology company focused on the discovery and development of revolutionary new treatments that engage the body’s immune system to benefit patients suffering from cancer. By combining multiple powerful platforms, Agenus has established a highly integrated approach for the discovery, development and manufacture of monoclonal and multi-specific antibodies that modulate targets of interest, as well as allogeneic cell therapies through its subsidiary MiNK therapeutics. In addition, the Company’s cancer vaccine program includes proprietary individualized and off-the-shelf vaccines uniquely designed for each patient. Agenus’ broad portfolio of novel checkpoint and other immuno-modulatory antibodies, cell therapies, vaccines and adjuvants, work in combination to provide the opportunity to create best-in-class therapeutic regimens. The Company has formed collaborations with BMS, Gilead, Merck and Incyte to discover and develop multiple checkpoint antibodies.

Press Releases
Sep 09, 2021
LEXINGTON, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Jennifer Buell,

btn News

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

btn Stock

SEC Filings

Form Description Filing date View
S-1

Registration statement for face-amount certificate companies

View HTML
S-1/A

Amended Registration statement for face-amount certificate companies

View HTML
8-A12G

Registration of certain classes of securities 12(g) of the Securities Exchange Act

View HTML
S-1/A

Amended Registration statement for face-amount certificate companies

View HTML

Data provided by Kaleidoscope.

btn SEC